




The relative strengths and weaknesses of Intercept Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intercept Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 140% points. The greatest weakness of Intercept Pharmaceuticals INC is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 373%, being 110% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	641,693
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	47,373
Liabilities, Non-Current	0
Other Assets	4,018
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	6,236
Other Net Income	5,509
Other Revenues	0
Property and Equipment	10,047
Research and Development	128,193
Selling, General and Administrative Expense	103,745

Output Variable	Value in 1000 USD
Assets	655,758
Liabilities	53,609
Expenses	231,938
Revenues	0
Stockholders Equity	602,149
Net Income	-226,429
Comprehensive Net Income	-226,429
BaseVar	473,407
ECR before LimitedLiability	306%
Economic Capital Ratio	373%